Navigation Links
Two-Drug Combo May Be Safe for Melanoma Treatment
Date:5/16/2012

By Randy Dotinga
HealthDay Reporter

WEDNESDAY, May 16 (HealthDay News) -- A preliminary, first-stage study funded by a pharmaceutical company shows promising results for an experimental double-drug therapy for melanoma.

The two drugs, known as dabrafenib and trametinib, appeared to delay progression of the potentially deadly skin cancer with fewer side effects than an existing drug called vemurafenib (Zelboraf).

However, the research into the drug combination is only in the first of three phases required before the U.S. government can approve its use. The first phase is designed to test the safety of a medication, not whether it works.

Unlike some other cancers, melanoma has stubbornly resisted advances in treatment. About 70,000 Americans are diagnosed with melanoma each year, and about 8,000 of those will die from the disease.

Researchers tested the drug combo in patients with advanced melanoma and a genetic mutation that exists in about half of all melanomas.

"Not only are the two drugs causing shrinkage of the cancer, but we're seeing that a second anti-cancer therapy may actually suppress the side effects of the first," said Dr. Jeffrey Weber, director of the Donald A. Adam Comprehensive Melanoma Research Center at the H. Lee Moffitt Cancer Center, Tampa, Fla., in a news release from the American Society of Clinical Oncologists.

Vemurafenib, approved last year, aims to prevent progression of the cancer in these patients. But patients' tumors eventually become immune to its effects.

The new analysis looks at 77 patients who took the combination therapy. Their cancer didn't progress for an average of 7.4 months, similar to what was seen in previous research with vemurafenib only. The researchers haven't released statistics about their survival rates.

Skin lesions, a side effect, were much less common in the patients on the combination therapy than in patients who took vemurafenib.

Ashani Weeraratna, an assistant professor in the Molecular and Cellular Oncogenesis Program at the Wistar Institute, Philadelphia, agreed that the combo therapy does seem to reduce the skin lesion side effects.

"This is important for patients that, in addition to battling a deadly disease, also have to deal with the discomfort associated with the secondary lesions," Weeraratna said. "Having said that, I do think most of us would pick getting what is essentially an uncomfortable rash over not receiving a cutting-edge therapy that might eradicate our metastatic melanoma."

Dr. Martin Weinstock, a professor of dermatology and epidemiology at Brown University in Providence, R.I., expressed some caution. "Ideally, what we need is to figure out how to cure most people with a regimen that doesn't have devastating side effects," he said. "We don't have that yet, and it doesn't look like this will be that either."

The results were scheduled for release Wednesday, prior to presentation June 4 at a meeting of the American Society of Clinical Oncologists in Chicago. The data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

The study was funded by the drug company GlaxoSmithKline, and Weber has received financial support from the pharmaceutical company.

More information

For more about melanoma, see the U.S. National Library of Medicine.

SOURCES: Martin Weinstock, M.D., Ph.D., professor of dermatology and epidemiology, Brown University, Providence, R.I.; Ashani T. Weeraratna, Ph.D., assistant professor, Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia; May 16, 2012, abstract, news release, American Society of Clinical Oncologists


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Two-Drug Combo Helps Teens With Migraines
2. Elderly Lung Cancer Patients Can Gain From Two-Drug Chemo: Study
3. Late-stage ovarian cancer shows promise in two-drug phase I trial
4. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
5. Experimental Chemo Combo for Colon Cancer Disappoints
6. New combo of chemo and well-known malaria drug delivers double punch to tumors
7. New Drug Combo for Hepatitis C Shows Promise
8. Two New Drug Combos May Fight Advanced Breast Cancers
9. Anti-estrogen combo better than single drug for hormone-sensitive breast cancer
10. Tender Breasts From Combo HRT Linked to Higher Cancer Risk
11. Combo hormone therapy has increased breast cancer risk over estrogen alone
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Two-Drug Combo May Be Safe for Melanoma Treatment
(Date:5/2/2016)... ... May 02, 2016 , ... “Engineering Bubbles,” an oil painting submitted ... ARRS Art Forum held recently at the Annual Meeting in Los Angeles. The first ... ARRS members and Annual Meeting attendees. , “Through art I hope to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Over $60 Billion is spent ... pet gear and toys, leading product review site for Toys, Tots, Pets & More ... at their Spring Showcase at the Metropolitan Pavilion in New York City. , ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... has announced a new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty ... the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled ...
(Date:5/2/2016)... ... ... According to an American Psychological Association article, the Centers for Disease ... of 18. Of those who survive, many still face effects as they reach adulthood. ... new book, Lyah! Lyah! Pants on Fyah!, she shares stories from women who are ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... Research & Analytics EVP and GM Jim Callandrillo and Duane Reed, VP ... 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... NEW YORK , May 2, 2016 /PRNewswire/ ... Series B financing of Graybug Vision, Inc. Graybug ... to developing therapies that may transform care for ... and glaucoma.  Graybug Vision,s technology was first developed ... out into a startup venture. ...
(Date:4/29/2016)... 2016  In the next ten years, the ... systems dependent on CRTs monitors to those reliant on ... Medical monitors and will automatically sync to existing ... foreseeable benefits to this technological advancement, it also ... to be replaced in order to be LCD ...
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
Breaking Medicine Technology: